As hospitals work to strengthen infection prevention protocols, many are unknowingly relying on UV-C devices that lack proper FDA authorization—putting patients, staff, and institutions at risk.
In Part 2 of Infection Control Today’s video interview series, Surfacide CEO Gunner Lyslo continues the conversation with IFC’s Tori Whitacre Martonicz, focusing on the legal and safety risks posed by unauthorized UV-C devices in clinical environments.
Key takeaways from Part 2:
- The difference between FDA and EPA jurisdiction over UV-C technologies
- Liabilities for using non-authorized devices in patient care areas
- The importance of asking vendors for FDA documentation and clearance specifics
